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Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease, characterized by loss 
of upper and lower motor neurons (MNs). It is well known that glutamate (Glu)-mediated 
excitotoxicity plays a major role in motor neuron damage and death, among several other 
cellular and molecular alterations. It has demonstrated that both excessive neuronal Glu 
release and defective glial Glu uptake contribute to increment the extracellular Glu levels and 
excitotoxicity.  
Aim 
We have investigated the release of Glu and the underlying mechanisms in spinal cord 
synaptosomes of SOD1G93A mice at a pre-symptomatic disease stage (30 days of life), in order 
to verify if the abnormal release occurs at this stage and to disclose the underlying 
mechanisms. 
Methods 
SOD1G93A mice expressing high copy number of mutant human SOD1 carrying the G93A point 
mutation, the most popular animal model, and age-matched wtSOD1 control mice are used. 
Synaptosomes were purified from SOD1 and SOD1G93A spinal cord by homogenization and 
separation on discontinuous Percoll® gradients. Glu release was studied in superfusion. Ca2+ 
concentration was measured by fluorometric analysis. Western blots were performed according 
to Laemmli et al. (1970). 
Results 
We found that both basal and high KCl- or ionomycin-evoked Glu release were more elevated 
in the spinal cord of pre-symptomatic SOD1G93A respect to control mice. The surplus of Glu 
release was exocytotic in nature, supported by an increase of the readily releasable pool of 
vesicles (RRP). As to the mechanisms sustaining the abnormal Glu release, we found elevated 
cytosolic Ca2+ levels  and increased phosphorylation of synapsin-I, that was causally related to 
the abnormal Glu release, being the latter normalized by entrapping synaptosomes with 
specific antibodies for synapsin-I phosphorylation sites. We also found increased 
phosphorylation of glycogen synthase kinase-3 at the inhibitory sites, an event that favours 
SNARE protein assembly, increased number of SNARE complexes at the nerve terminal 
membrane, with no changes of SNARE protein expression, and increased expression of 
synaptotagmin-1 and β-Actin, out of an array of release-related presynaptic proteins whose 
expressions were unmodified.  
Conclusion 
Abnormal exocytotic Glu release occurs in the spinal cord of pre-symptomatic SOD1G93A mice, 
similarly to what previously observed in late symptomatic SOD1G93A mice. It mainly bases on 
an increased size of the RRP and on release facilitation; two events supported by plastic 
changes of specific pre-synaptic protein expression and function. Our results suggest that 
similar mechanisms can support the abnormal Glu release at pre- and late symptomatic stages 
of the disease. The precociousness of this phenomenon may imply that it represents a cause of 
the disease rather than a consequence of the neuronal damage during disease progression. 
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